• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Evolving therapeutic goals in Crohn's disease management.克罗恩病管理中不断演变的治疗目标
United European Gastroenterol J. 2020 Mar;8(2):133-139. doi: 10.1177/2050640619887316. Epub 2019 Nov 4.
2
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.紧密控制管理对克罗恩病(CALM)的影响:一项多中心、随机、对照的 3 期临床试验。
Lancet. 2017 Dec 23;390(10114):2779-2789. doi: 10.1016/S0140-6736(17)32641-7. Epub 2017 Oct 31.
3
Impact of therapies on bowel damage in Crohn's disease.治疗对克罗恩病肠道损伤的影响。
United European Gastroenterol J. 2020 May;8(4):410-417. doi: 10.1177/2050640620908696. Epub 2020 Feb 20.
4
Higher Adalimumab Drug Levels are Associated with Mucosal Healing in Patients with Crohn's Disease.阿达木单抗药物水平升高与克罗恩病患者的黏膜愈合相关。
J Crohns Colitis. 2016 May;10(5):510-5. doi: 10.1093/ecco-jcc/jjw014. Epub 2016 Jan 18.
5
Normalization of C-Reactive Protein Predicts Better Outcome in Patients With Crohn's Disease With Mucosal Healing and Deep Remission.C反应蛋白正常化预示着克罗恩病患者黏膜愈合及深度缓解的更好结局。
Clin Transl Gastroenterol. 2020 Feb;11(2):e00135. doi: 10.14309/ctg.0000000000000135.
6
Natural history, diagnosis and treatment approach to fibrostenosing Crohn's disease.纤维狭窄性克罗恩病的自然史、诊断和治疗方法。
United European Gastroenterol J. 2020 Apr;8(3):263-270. doi: 10.1177/2050640620901960. Epub 2020 Jan 14.
7
[Adalimumab for the treatment of adult Crohn's disease--update of a consensus report by the Working Group Inflammatory Bowel Disease of the Austrian Society of Gastroenterology and Hepatology].[阿达木单抗治疗成人克罗恩病——奥地利胃肠病学和肝病学会炎症性肠病工作组共识报告更新]
Z Gastroenterol. 2013 Sep;51(9):1101-9. doi: 10.1055/s-0033-1350165. Epub 2013 Aug 30.
8
Clinical, biological, and endoscopic responses to adalimumab in antitumor necrosis factor-naive Crohn's disease: predictors of efficacy in clinical practice.抗肿瘤坏死因子初治的克罗恩病患者对阿达木单抗的临床、生物学及内镜反应:临床实践中疗效的预测因素
Eur J Gastroenterol Hepatol. 2015 Apr;27(4):430-5. doi: 10.1097/MEG.0000000000000296.
9
Antitumor Necrosis Factor Agents to Treat Endoscopic Postoperative Recurrence of Crohn's Disease: A Nationwide Study With Propensity-Matched Score Analysis.抗肿瘤坏死因子制剂治疗克罗恩病内镜术后复发:一项全国性研究及倾向评分匹配分析。
Clin Transl Gastroenterol. 2020 Aug;11(8):e00218. doi: 10.14309/ctg.0000000000000218.
10
Serological Biomarkers of Tissue Turnover Identify Responders to Anti-TNF Therapy in Crohn's Disease: A Pilot Study.血清学组织转换标志物可识别克罗恩病抗 TNF 治疗的应答者:一项初步研究。
Clin Transl Gastroenterol. 2020 Sep;11(9):e00217. doi: 10.14309/ctg.0000000000000217.

引用本文的文献

1
Therapeutic sequencing in inflammatory bowel disease: Determining the optimal position of vedolizumab for long-term Crohn's disease control using real-world evidence.炎症性肠病的治疗序贯策略:利用真实世界证据确定vedolizumab 在长期克罗恩病控制中的最佳位置。
United European Gastroenterol J. 2024 Jun;12(5):574-584. doi: 10.1002/ueg2.12563. Epub 2024 May 8.
2
Patient and Health Care Professional Perceptions of the Experience and Impact of Symptoms of Moderate-to-Severe Crohn's Disease in US and Europe: Results from the Cross-Sectional CONFIDE Study.患者和医护人员对美国和欧洲中重度克罗恩病症状的体验和影响的认知:来自横断面 CONFIDE 研究的结果。
Dig Dis Sci. 2024 Jul;69(7):2333-2344. doi: 10.1007/s10620-024-08434-5. Epub 2024 May 3.
3
Magnetic Resonance Enterography Assessment of Transmural Healing with Vedolizumab in Moderate to Severe Crohn's Disease: Feasibility in the VERSIFY Phase 3 Clinical Trial.维多珠单抗治疗中重度克罗恩病透壁愈合的磁共振小肠造影评估:VERSIFY 3期临床试验的可行性
Clin Exp Gastroenterol. 2024 Jan 27;17:9-23. doi: 10.2147/CEG.S429039. eCollection 2024.
4
How many biomarker measurements are needed to predict prognosis in Crohn's disease patients under infliximab?-A prospective study.需要多少生物标志物测量来预测英夫利昔单抗治疗的克罗恩病患者的预后?一项前瞻性研究。
United European Gastroenterol J. 2023 Jul;11(6):531-541. doi: 10.1002/ueg2.12420. Epub 2023 Jun 15.
5
A Regional Survey of Awareness of Inflammatory Bowel Disease among the Saudi Population.沙特人群中炎症性肠病认知情况的区域调查
Inflamm Intest Dis. 2023 Feb 15;7(3-4):139-146. doi: 10.1159/000529318. eCollection 2023 Mar.
6
A scoping review on early inflammatory bowel disease: definitions, pathogenesis, and impact on clinical outcomes.早期炎症性肠病的范围综述:定义、发病机制及对临床结局的影响
Therap Adv Gastroenterol. 2022 Dec 19;15:17562848221142673. doi: 10.1177/17562848221142673. eCollection 2022.
7
Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues.肿瘤坏死因子抑制剂治疗炎症性肠病:故事仍在继续。
Therap Adv Gastroenterol. 2021 Dec 9;14:17562848211059954. doi: 10.1177/17562848211059954. eCollection 2021.

本文引用的文献

1
Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease.1 年深度缓解可预防早期克罗恩病进展。
Gastroenterology. 2020 Jul;159(1):139-147. doi: 10.1053/j.gastro.2020.03.039. Epub 2020 Mar 26.
2
Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn's Disease.乌司奴单抗对克罗恩病患者组织学疾病活动的影响。
Gastroenterology. 2019 Oct;157(4):1019-1031.e7. doi: 10.1053/j.gastro.2019.06.037. Epub 2019 Jul 4.
3
Proactive Infliximab Drug Monitoring Is Superior to Conventional Management in Inflammatory Bowel Disease.主动英夫利昔单抗药物监测优于炎症性肠病的常规治疗。
Inflamm Bowel Dis. 2020 Jan 6;26(2):263-270. doi: 10.1093/ibd/izz131.
4
Development and Validation of a Simplified Magnetic Resonance Index of Activity for Crohn's Disease.简化的克罗恩病磁共振活动指数的制定与验证。
Gastroenterology. 2019 Aug;157(2):432-439.e1. doi: 10.1053/j.gastro.2019.03.051. Epub 2019 Apr 3.
5
Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.较短的疾病病程与克罗恩病患者对维得利珠单抗的更高应答率相关,但与溃疡性结肠炎无关。
Clin Gastroenterol Hepatol. 2019 Nov;17(12):2497-2505.e1. doi: 10.1016/j.cgh.2018.12.040. Epub 2019 Jan 6.
6
Clinical Outcomes With Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Systematic Review With Meta-Analysis.治疗药物监测在炎症性肠病中的临床结局:系统评价与荟萃分析。
J Crohns Colitis. 2018 Nov 15;12(11):1302-1315. doi: 10.1093/ecco-jcc/jjy109.
7
Accuracy of Diffusion-weighted Magnetic Resonance Imaging in Detecting Mucosal Healing and Treatment Response, and in Predicting Surgery, in Crohn's Disease.弥散加权磁共振成像在检测黏膜愈合和治疗反应,以及预测克罗恩病手术中的准确性。
J Crohns Colitis. 2018 Nov 9;12(10):1180-1190. doi: 10.1093/ecco-jcc/jjy098.
8
Comparative Accuracy of Bowel Ultrasound Versus Magnetic Resonance Enterography in Combination With Colonoscopy in Assessing Crohn's Disease and Guiding Clinical Decision-making.肠超声与磁共振肠造影术联合结肠镜检查评估克罗恩病及指导临床决策的准确性比较。
J Crohns Colitis. 2018 Nov 15;12(11):1280-1287. doi: 10.1093/ecco-jcc/jjy093.
9
Ultrasound for Assessing Disease Activity in IBD Patients: A Systematic Review of Activity Scores.超声评估 IBD 患者的疾病活动度:活动评分的系统评价。
J Crohns Colitis. 2018 Jul 30;12(8):920-929. doi: 10.1093/ecco-jcc/jjy048.
10
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.紧密控制管理对克罗恩病(CALM)的影响:一项多中心、随机、对照的 3 期临床试验。
Lancet. 2017 Dec 23;390(10114):2779-2789. doi: 10.1016/S0140-6736(17)32641-7. Epub 2017 Oct 31.

克罗恩病管理中不断演变的治疗目标

Evolving therapeutic goals in Crohn's disease management.

作者信息

Chateau Thomas, Peyrin-Biroulet Laurent

机构信息

FDepartment of Hepato-Gastroenterology, University Hospital of Grenoble, University of Grenoble Alpes, Grenoble, France.

FDepartment of Gastroenterology and Inserm NGERE, University Hospital of Nancy, University of Lorraine, Vandoeuvre-lès-Nancy, France.

出版信息

United European Gastroenterol J. 2020 Mar;8(2):133-139. doi: 10.1177/2050640619887316. Epub 2019 Nov 4.

DOI:10.1177/2050640619887316
PMID:32213074
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7079266/
Abstract

The main objectives in Crohn's disease are to avoid disease complications and preserve the patient's quality of life. Early disease control and close monitoring with specific targets to reach might be the only way to change the disease course. In two decades, we have moved from clinical response to full remission (clinical and endoscopic remission) requiring a tight monitoring of both symptoms and objective signs of inflammation. This review summarizes the concepts of tight control and treat-to-target and their potential for disease modification.

摘要

克罗恩病的主要目标是避免疾病并发症并维持患者的生活质量。早期疾病控制以及针对特定目标进行密切监测可能是改变疾病进程的唯一途径。在过去二十年中,我们已经从关注临床反应转变为追求完全缓解(临床和内镜下缓解),这需要对症状和炎症客观体征进行严格监测。本综述总结了严格控制和达标治疗的概念及其改变疾病的潜力。